Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Explore available award and grant opportunities for fellows-in-training.
Make a choice that matters
The best care starts with the best information
Have you seen the Division Director toolkit?
2019 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease (final publication of guideline anticipated in late 2019)
The public comment period for the 2019 Draft Clinical Practice Guideline: Prevention, Diagnosis and Treatment of Lyme Disease has closed. Public comments were accepted from June 26 - September 9, 2019, and are now being closely reviewed before a final guideline is published.
The IDSA, AAN, and ACR are jointly developing a systematic review and guideline on treatment of Lyme disease. The author composition is made up of representatives from IDSA, AAN, and ACR with representation from the American Academy of Family Physicians (AAFP), American Academy of Pediatrics - Committee on Infectious Diseases (AAP-COID), American Academy of Pediatrics - Section on Emergency Medicine (AAP-EM), American College of Physicians (ACP), Association of Medical Microbiology and Infectious Diseases - Canada (AMMI-CA), Child Neurology Society (CNS), Pediatric Infectious Diseases Society (PIDS), Entomological Society of America (ESA), and European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Members representing the disciplines of cardiology, microbiology, pathology, and a methodologist with expertise in GRADE are also included. Finally, the panel includes a healthcare consumer representative, three patients with confirmed Lyme disease, and a parent of a pediatric patient with confirmed Lyme disease.
The societies are utilizing the IDSA guideline development process, which includes the widely accepted GRADE methodology and are adhering to the Institute of Medicine (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines. These rigorous standards are meant to assure objective, transparent, and scientifically valid systematic reviews and clinical practice guidelines.
In 2015, the guideline panel held a public comment period requesting input on its project plan that laid the ground work for new Lyme disease guidelines. The panel has published its response to the input received during the public comment period.